

Patient Organisation disclosure template						
PO name	Country	Types of the support or services provided	Description of the support or services ¹	Monetary value of financial support and of invoiced costs	Non-monetary benefit for PO ²	Fees for services paid
Arthritis Ireland	Ireland	Financial support	Support Arthritis Ireland clinical referral service and and Organisation's anniversary event	10,000	0	0
Irish Cancer Society	Ireland	Financial support	Support for the annual Survivorship Conference	10,000	0	0
Irish Soc Colitis/Crohns Dis	Ireland	Financial support	Core funding to support patient services	3,000	0	0
Men Against Cancer	Ireland	Financial support	Publication of a prostate cancer quality of life survey	5,000	0	0
Multiple Myeloma Ireland	Ireland	Financial Support	Core funding to support organisation's activities	7,500	0	0
PHA Ireland	Ireland	Financial support	Funding to support patient education and meetings	10,000	0	0
Rare Diseases Ireland	Ireland	Financial support	Industry membership of RDI, supporting organisation's operational costs	3,500	0	0

¹: Add a clear description of the purpose of the support or services

²: For example, employee hours or companies facilities offered to support a Patient Organisation activity

Janssen disclosure methodology for 2022 **(Patient Organisations)**

1. Introduction

The information below describes the methodology that Janssen Sciences Ireland UC (Janssen) has applied to disclose the Transfers of Value (ToV) made to Patient Organisations (POs) in the submission to the Irish Pharmaceutical Healthcare Association (IPHA) for 2022.

2. Which payments will be included?

The following types of payments to identified POs (as defined in Annex 3 of the IPHA Code of Practice for the Pharmaceutical Industry) are disclosed:

- Companies may donate money without reference to the specific purpose for which it is to be used. This is sometimes referred to as a contribution to core funding;
- Funding may be provided for a PO publication, meeting, project or piece of research in which the company has little or no involvement;
- A company may facilitate PO meetings by providing or sponsoring speakers or providing a venue or making a contribution towards travel expenses for delegates;
- A company may undertake projects of joint interest with a PO.

In addition to payments defined by the IPHA code, Janssen will also include

- Fee for services- Payments made to POs for their time and contributions to Janssen work/projects

3. What rules have Janssen applied to be included for disclosure?

The following rules apply:

- All direct and indirect payments to POs will be included in the calendar year in which Janssen executed the payment in our financial systems.

4. How does Janssen report non-monetary value for ToV for benefits in kind made to POs?

Janssen discloses benefits in kind using the fair market value listed in the contract between Janssen and the PO.

5. How does Janssen report ToV related to multi-year contracts?

For contracts that span multiple years, typically a split payment approach is used. This means that the total value is transferred in separate payments over time.

Each of these separate payments will be included in Janssen disclosure numbers for the calendar year in which Janssen executed the actual payment in our financial systems.

6. Is VAT included?

Direct payments are disclosed exclusive of VAT and inclusive of withholding tax, if applicable.

All ToVs for travel and accommodation (e.g., flight ticket, hotel room, etc.) are reported inclusive of VAT, where applicable.

The disclosure reported ToV amounts should not be used for VAT/Tax reporting purposes. If fiscal reports are required, the company provides them directly to the POs.

7. Which Janssen companies have a duty to disclose ToVs?

Janssen is a member of the IPHA. Janssen has a code requirement to disclose all ToVs made to POs based in Ireland.

Disclaimer

Janssen relies on a combination of automated systems, standardised processes, and manual data entry from internal and external resources to record and report relevant ToV data. The information reported in this submission is done in good faith and best efforts to comply with the requirements of the IPHA Disclosure Code. Although Janssen strive for efficient and fast processing, it might occur that payment information becomes available only after the date of publishing. Should we, despite our best efforts to ensure accurate reporting, fail to include complete and correct information in our submission, we will appropriately investigate and address in case of erroneous information. Janssen expect this to be exceptional and will monitor actual occurrences. In case of significant changes to the initial publication Janssen will publish an amendment within a reasonable timeframe.

Should a PO consider that the report is incomplete or incorrect, please contact us via disclosure@janssen.ie and we will make appropriate changes as soon as possible.